Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Ex-BARDA Chief: I Was Removed For Resisting Trump’s ‘Game Changer’ Drug

Furor Comes As Novartis Prepares Trial To Answer Data Doubts

Executive Summary

Former BARDA leader says science not politics has to lead COVID-19 decision making. Plus Bayer launches Canada partnership, Korea pools research efforts.

You may also be interested in...



US FDA Safety Alert For Hydroxychloroquine Is Latest Turn In Drug's Strange Journey

As potentially life-threatening heart problems emerge in coronavirus patients, FDA says hydroxychloroquine should be taken only in clinical trial or hospital settings under the Emergency Use Authorization.

Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies

Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.

Coronavirus Update: Moderna Lifted By BARDA funding, Europe Looks For Exit Strategy, Vaccine Funds

Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel